Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: A retrospective cohort study

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Grima, Daniel T ^a,b   Papaioannou, Alexandra ^c   Airia, Parisa ^a   Ioannidis, George ^c   Adachi, Jonathan D ^b,c  

^a Department of Data Analytics and Evidence Synthesis   (Canada)

^b Center for Osteoporosis and Arthritis Research and Education (COARE)   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; ESTROGEN; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; VITAMIN D; BONE DENSITY CONSERVATION AGENT; GENERIC DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOATING; BONE DENSITY; BONE PAIN; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DIVERTICULOSIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEMUR; FLANK PAIN; GASTROINTESTINAL DISEASE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HIGH RISK PATIENT; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; NAUSEA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RASH; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; SPINE; STOMACH PAIN; STOMACH ULCER; STUDENT T TEST; TERTIARY HEALTH CARE; THORAX PAIN; BONE; CHEMICALLY INDUCED DISORDER; COST BENEFIT ANALYSIS; DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHARMACOKINETICS; PHYSIOLOGY; RADIOGRAPHY; RISK FACTOR; STATISTICS; STOMACH MUCOSA;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUGS, GENERIC; FEMALE; FEMUR; GASTRIC MUCOSA; GASTROINTESTINAL DISEASES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; RISK FACTORS; SPINE; THERAPEUTIC EQUIVALENCY;

EID: 77950677409     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-68     Document Type: Article

References (22)

1. Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). A Tenenhouse L Joseph N Kreiger S Poliquin TM Murray L Blondeau C Berger DA Hanley JC Prior CaMos Research Group Canadian Multicentre Osteoporosis Study, Osteoporos Int 2000 11 10 897 904 10.1007/s001980070050 11199195
2. The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. A Papaioannou CC Kennedy G Ioannidis Y Gao AM Sawka D Goltzman A Tenenhouse L Pickard WP Olszynski KS Davison S Kaiser RG Josse N Kreiger DA Hanley JC Prior JP Brown T Anastassiades JD Adachi CaMos Research Group, Osteoporos Int 2008 19 4 581 587 10.1007/s00198-007-0483-0 17924051
3. Fragility fractures and the osteoporosis care gap: an international phenomenon. L Giangregorio A Papaioannou A Cranney N Zytaruk JD Adachi, Semin Arthritis Rheum 2006 35 5 293 305 10.1016/j.semarthrit.2005.11.001 16616152
4. The osteoporosis care gap in Canada. A Papaioannou L Giangregorio B Kvern P Boulos G Ioannidis JD Adachi, BMC Musculoskelet Disord 2004 5 11 10.1186/1471-2474-5-11 15068488
5. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? B Cryer DC Bauer, Mayo Clin Proc 2002 77 10 1031 1043 10.4065/77.10.1031 12374247
6. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud, Lancet 1996 348 9041 1535 1541 10.1016/S0140-6736(96)07088-2 8950879
7. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. UA Liberman SR Weiss J Bröll HW Minne H Quan NH Bell J Rodriguez-Portales RW Downs Jr J Dequeker M Favus, N Engl J Med 1995 333 22 1437 1443 10.1056/NEJM199511303332201 7477143
8. Safe and efficacious nonhormonal therapy. JD Adachi, Can Fam Physician 1998 44 327 332 9512836
9. Adverse effects of bisphosphonates. A comparative review. S Adami N Zamberlan, Drug Saf 1996 14 3 158 170 10.2165/00002018-199614030-00003 8934578
10. Absorption of oral diphosphonate in normal subjects. I Fogelman L Smith R Mazess MA Wilson JA Bevan, Clin Endocrinol (Oxf) 1986 24 1 57 62 10.1111/j.1365-2265.1986.tb03254.x 3085989
11. Alendronate reduces the risk of vertebral fractures in women without pre-existing vertebral fractures: results of the Fracture Intervention Trial. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix for the Fracture Intervention Trial Research Group, JAMA 1998 280 24 2077 2082 10.1001/jama.280.24.2077 9875874
12. Disintegration/dissolution profiles of copies of Fosamax (alendronate). S Epstein B Cryer S Ragi JR Zanchetta J Walliser J Chow MA Johnson AE Leyes, Curr Med Res Opin 2003 19 8 781 789 10.1185/030079903125002577 14687450
13. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. H Halkin M Dushenat B Silverman V Shalev R Loebstein Y Lomnicky N Friedman, Ann Pharmacother 2007 41 1 29 34 17190847
14. Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate. M Shakweh I Bravo-Osuna G Ponchel, Eur J Pharm Sci 2007 31 5 262 270 10.1016/j.ejps.2007.03.012 17576054
15. Disintegration and esophageal irritation profiles of alendronate formulations: implications for clinical safety and efficacy. S Epstein P Geusens JE Fisher SL Hill S Roy G Rodan N Muniappa GK Wollenberg L Handt N Kelly, J Appl Res 2005 5 253 265
16. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects. AC Perkins PE Blackshaw PD Hay SC Lawes CT Atherton RJ Dansereau LK Wagner DJ Schnell RC Spiller, Clin Ther 2008 30 5 834 844 10.1016/j.clinthera. 2008.04.018 18555931
17. In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US. RJ Dansereau DJ Crail AC Perkins, Curr Med Res Opin 2009 25 2 449 452 10.1185/03007990802648903 19192989
18. Use of generic alendronate in the treatment of osteoporosis. National Osteoporosis Foundation of South Africa, S Afr Med J 2006 96 8 696 697 17019490
19. Differences in persistence among different weekly oral bisphosphonate medications. O Sheehy CM Kindundu M Barbeau J Lelorier, Osteoporos Int 2008 19020921
20. Generic substitution of antihypertensive drugs: does it affect adherence? BL Van Wijk OH Klungel ER Heerdink A de Boer, Ann Pharmacother 2006 40 1 15 20 16303985
21. The impact of generic-only drug benefits on patients' use of inhaled corticosteroids in a Medicare population with asthma. V Fung IB Tager R Brand JP Newhouse J Hsu, BMC Health Serv Res 2008 8 151 10.1186/1472-6963-8-151 18638405
22. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. JD Ringe G Möller, Rheumatol Int 2009